Kutki is a bitter Himalayan root: a large animal literature on liver protection, almost no human evidence. Loose stools and cramping are common, dose-related, reversible. The larger hazard is the supply chain: toxic metals and species substitution. With measurable liver abnormalities and a batch-tested product, it presents as a low-cost, short-course option whose promise the trials have yet to keep. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Alanine aminotransferase (ALT) | Under 25 U/L (men), under 20 U/L (women) | Most sensitive routine marker of liver cell injury |
| Aspartate aminotransferase (AST) | Under 25 U/L | Paired with ALT; ratio above 2 points toward alcohol |
| Gamma-glutamyl transferase (GGT) | Under 20 U/L | Tracks bile flow and oxidative stress; often the first to move |
| Total bilirubin | 0.3–1.0 mg/dL | The endpoint that moved in the only controlled trial |
| Alkaline phosphatase (ALP) | 50–90 U/L | Distinguishes bile duct obstruction from liver cell injury |
| Whole-blood lead | Under 1.0 µg/dL | Direct check on the contamination risk in this product category |
| Glycated haemoglobin (HbA1c) | 4.8–5.4% | Metabolic context for fatty liver; safety check with glucose-lowering drugs |
| Liver fat fraction on imaging | Under 5% | The only direct measure of the targeted outcome |
| Fasting triglycerides | Under 100 mg/dL | Tracks the metabolic driver of liver fat |
Cadence: Liver panel at 8–12 weeks, then every 6 months; glucose markers at 12 weeks if a glucose-lowering medication is taken; imaging only at 6–12 months